

Product Data Sheet

Product Name: S18886
Cat. No.: GC17410

Chemical Properties

Cas. No. 165538-40-9

Chemical Name (6R)-6-[[[(4-chlorophenyl)sulfonyl]amino]-5,6,7,8-tetrahydro-2-methyl-1-naphthalenepropanoic

SMILES CC1=C(CCC(O)=O)C2=C(C=C1)C[C@H](NS(C3=CC=C(Cl)C=C3)(=O)=O)CC2

Formula $C_{20}H_{22}ClNO_4S$ M.Wt 407.9


Solubility $\leq 2\text{mg/ml}$ in ethanol; 30mg/ml in DMSO; 30mg/ml in dimethyl formamide

Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37°C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Background

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

IC₅₀: 16.4 nM for TP receptor

S18886 is a potent thromboxane A₂ (TP) inhibitor.

The lipid mediator thromboxane A₂ (TXA₂) plays a critical role in platelet aggregation and vascular and bronchial smooth muscle constriction. The actions of TXA₂ are mediated via the specific G protein coupled-receptor, TXA₂ receptor (TP).

In vitro: S18886 was identified as the active isomer of the potent TP receptor antagonist S18204. S18886 was also found to be a selective antagonist of thromboxaneprostaglandin receptors in platelets and in the vessel wall [1].

In vivo: In a previous animal study, it was found that S18886 treatment could reduce the portal pressure in both animal models without producing significant changes in portal blood flow, indicating a reduction in hepatic vascular resistance. S18886 could not significantly change arterial pressure in CCl₄ -cirrhotic rats but could significantly decrease it in BDL-cirrhotic rats [2].

Clinical trial: A previous trial aiming to evaluate S18886 versus aspirin in patients with cerebral ischaemic events showed similar rates of the primary endpoint with S18886 and aspirin, without safety advantages for S18886 [3].

References:

- [1] Cimetière B, Dubuffet T, Landras C, Descombes JJ, Simonet S, Verbeuren TJ, Lavielle G. New tetrahydronaphthalene derivatives as combined thromboxane receptor antagonists and thromboxane synthase inhibitors. *Bioorg Med Chem Lett*. 1998 Jun 2;8(11):1381-6.
- [2] Rosado E, Rodríguez-Vilarrupla A, Gracia-Sancho J, Tripathi D, García-Calderó H, Bosch J, García-Pagán JC. Terutroban, a TP-receptor antagonist, reduces portal pressure in cirrhotic rats. *Hepatology*. 2013 Oct;58(4):1424-35.
- [3] Bousser MG, Amarenco P, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, de Cordoue A, Fratacci MD; PERFORM Study Investigators. Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. *Lancet*. 2011 Jun 11;377(9782):2013-22.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA